Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor ModelsJIE LIN; SAMPATH, Deepak; LEE, Leslie B et al.Clinical cancer research (Print). 2013, Vol 19, Num 7, pp 1760-1772, issn 1078-0432, 13 p.Article

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In VivoWALLIN, Jeffrey J; GUAN, Jane; PRIOR, Wei Wei et al.Clinical cancer research (Print). 2012, Vol 18, Num 14, pp 3901-3911, issn 1078-0432, 11 p.Article

P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type MelanomaONG, Christy C; JUBB, Adrian M; HARRIS, Adrian L et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 9, pp 606-615, issn 0027-8874, 10 p.Article

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical ResponseWONG, Harvey; CHOO, Edna F; GOULD, Stephen E et al.Clinical cancer research (Print). 2012, Vol 18, Num 14, pp 3846-3855, issn 1078-0432, 10 p.Article

Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid TumorsEDGAR, Kyle A; WALLIN, Jeffrey J; BERRY, Megan et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 3, pp 1164-1172, issn 0008-5472, 9 p.Article

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth InhibitionHOEFLICH, Klaus P; MERCHANT, Mark; ENGST, Stefan et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 1, pp 210-219, issn 0008-5472, 10 p.Article

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthHATZIVASSILIOU, Georgia; KYUNG SONG; MORALES, Tony et al.Nature (London). 2010, Vol 464, Num 7287, pp 431-435, issn 0028-0836, 5 p.Article

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAF^V600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway SuppressionHOEFLICH, Klaus P; HERTER, Sylvia; STERN, Howard et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 7, pp 3042-3051, issn 0008-5472, 10 p.Article

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of CancerFOLKES, Adrian J; AHMADI, Khatereh; FRIEDMAN, Lori S et al.Journal of medicinal chemistry (Print). 2008, Vol 51, Num 18, pp 5522-5532, issn 0022-2623, 11 p.Article

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical ModelsSPOERKE, Jill M; O'BRIEN, Carol; FRIEDMAN, Lori S et al.Clinical cancer research (Print). 2012, Vol 18, Num 24, pp 6771-6783, issn 1078-0432, 13 p.Article

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical ModelsO'BRIEN, Carol; WALLIN, Jeffrey J; BEIVIN, Marcia et al.Clinical cancer research (Print). 2010, Vol 16, Num 14, pp 3670-3683, issn 1078-0432, 14 p.Article

Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinaseSTABEN, Steven T; HEFFRON, Timothy P; LESNICK, John et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 20, pp 6048-6051, issn 0960-894X, 4 p.Article

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer ModelsHOEFLICH, Klaus P; O'BRIEN, Carol; WEI ZHOU et al.Clinical cancer research (Print). 2009, Vol 15, Num 14, pp 4649-4664, issn 1078-0432, 16 p.Article